Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· July 27, 2026

Baker Hughes targets Horizon 2 IET orders above $45B as it forecasts $27.35B 2026 revenue and integrates Chart

View original at seekingalpha.com
Baker Hughes targets Horizon 2 IET orders above $45B as it forecasts $27.35B 2026 revenue and integrates Chart Earnings Call Insights: Baker Hughes (BKR) Q2 2026 MANAGEMENT VIEW * Chairman, President & CEO Lorenzo Simonelli framed Q2 as a quarter where “disciplined execution and the strength of our diversified portfoli…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q3 2026 guidance is company revenue of $6.87 billion and adjusted EBITDA of $1.205 billion, assuming Middle East activity remains broadly unchanged through year-end

    60% confidence
  • Asked about the drivers of record IET orders and margins on recent orders

    60% confidence
  • Baker Hughes is not providing Chart segment guidance today and will provide updated guidance ahead of Q3 earnings

    60% confidence
  • Uncertainty centers on project timing, local supply chains, Gas Tech equipment backlog conversion, and the aeroderivative supply chain; free cash strength reflected milestone and advanced payments, with working capital driving quarter-to-quarter variability

    60% confidence
  • GAAP diluted EPS was $0.68; excluding $0.04 of adjusting items, adjusted diluted EPS was $0.64

    60% confidence
  • OFSE revenue was $3.45 billion, EBITDA $605 million, margin 17.5%, a significantly stronger-than-anticipated quarter despite Middle East disruptions

    60% confidence
  • Data centers are one of the clearest near-term commercial opportunities with Chart, alongside actionable gas infrastructure opportunities across hydrogen, helium, CO2, nitrogen, oxygen, and longer-term adjacencies in space, geothermal and mining

    60% confidence
  • Chart will operate as Baker Hughes' third reporting segment with integration driven through 18 work streams

    60% confidence
  • OFS outperformance came from stronger activity outside the Middle East, better-than-anticipated Middle East product revenue, and SSPS revenue up about 10% sequentially

    60% confidence
  • IET orders doubled year-over-year to a record $7.1 billion with a 2.2x book-to-bill ratio and RPO up 19% to an all-time high of $37.1 billion

    60% confidence
  • Asked what drove OFS outperformance and the moving parts for the second half

    60% confidence
  • Asked about capacity expansion plans through 2029 and implications for mix, pricing, and CapEx

    60% confidence
  • Disciplined execution and diversified portfolio offset anticipated Middle East headwinds

    60% confidence
  • Given longer GTE cycle times, a meaningful portion of the GTE order mix extends beyond 2027

    60% confidence
  • New gas turbine/generator capacity coming online by 2029 could support nearly $5 billion in annual Power Systems revenue opportunity at full utilization

    60% confidence
  • Asked about puts/takes for IET in the second half and why free cash flow conversion was unchanged

    60% confidence
  • The expected $5 billion of annualized revenue capacity by 2029 implies roughly a 3-4x increase versus ~$1 billion last year, with paybacks below 2 years and gas turbines representing roughly half the opportunity

    60% confidence
  • Horizon 2 IET orders are now expected to exceed $45 billion, up from a prior expectation of exceeding $40 billion, supported by $12 billion of IET orders year-to-date

    60% confidence
  • FY2026 revenue and adjusted EBITDA are now expected to modestly exceed prior expectations, guided to $27.35 billion revenue and $4.85 billion adjusted EBITDA

    60% confidence
  • IET revenue was $3.3 billion, EBITDA $678 million, margin 20.6%, driven by favorable backlog pricing and Baker Hughes Business System execution

    60% confidence
  • Following the Chart acquisition, leverage will temporarily increase, with a return to 1-1.5x net leverage expected within 24 months

    60% confidence
  • Adjusted EPS was $0.64 with a record 18.3% adjusted EBITDA margin

    60% confidence
  • Full-year IET orders guidance raised to $17.5-$19.5 billion, with IET revenue midpoint at $13.5 billion (assuming Waygate closes at year-end) and IET EBITDA midpoint of $2.725 billion

    60% confidence
  • Asked about commercial synergies with Chart

    60% confidence
  • Q2 adjusted EBITDA was $1.23 billion, exceeding the high end of guidance

    60% confidence
  • Record IET orders were driven by data centers, LNG, and gas processing, including $2.6 billion of Power Systems orders (~150 gas turbines), with data centers accounting for $2.2 billion of Power Systems orders; pricing discipline supports IET margins in 2027 and beyond

    60% confidence
  • Total company bookings were $10.5 billion with free cash flow of $1.1 billion and net debt to adjusted EBITDA declining to 0.1x

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com